Embedded Files
The UK Vaccine Innovation Pathway (VIP) Programme Management Office (PMO) is launching the Vaccine Innovation Fund call to support projects that aim to address the following challenges:
Clinical trials pharmacy: building capacity and capability, focus on ATMPs.
Widening participation in clinical trials with a focus in primary, residential care and community settings.
Through this call, awards between £200,000 and £500,000 for a period of up to 2 years are available for eligible pilot projects. Please note that this will be a single stage application.
Pilot projects should have clearly defined proposals which specifically target one or more of the challenges identified in the guidance. Projects should set out how the outcomes of the projects will be scaled up to accelerate vaccine clinical trials across the UK.
We will not accept applications which have not secured the support of the corresponding Integrated Care System (ICS) in England or Health and Care Research Wales, NHS Research Scotland and NI Health and Social where the lead organisations are based in the devolved administrations.
The information below is about the Vaccine Innovation Fund, including details of the Workshop introducing the Fund, and a Frequently Asked Questions document for applicants.
If you have any issues accessing files or videos on this page, please contact vip@nihr.ac.uk.Webinar
Webinar
The Vaccine Innovation Pathway PMO, in partnership with Moderna, hosted a webinar to support applications on Tuesday 27th February.
The webinar slides can be found here, a recording of the webinar can be found below:
Vaccine Innovation Fund Workshop Recording 27 Feb 2024.movFAQs
FAQs
Please click here to download the FAQs document (last updated 28 March 2024).
About the UK Vaccine Innovation Pathway and Vaccine Innovation Fund
About the UK Vaccine Innovation Pathway and Vaccine Innovation Fund
The COVID-19 pandemic provided an opportunity for the UK to showcase its capabilities in vaccine research and development, further solidifying its position as a global leader in this critical area of public health.
The UK Vaccine Innovation Pathway (VIP) programme represents a strategic initiative to capitalise on the momentum and expertise gained during the COVID-19 pandemic in vaccine research and development. By leveraging the innovative approaches and research assets established during the pandemic, the programme aims to expedite the clinical trial process for vaccines and cement the UK's position as a global leader in this vital area of public health.
The VIP is a cross-sector programme supporting The Future of UK Clinical Research Delivery – a collective vision which aims to achieve faster, more efficient and more innovative clinical research delivery – making the UK one of the best places in the world to conduct research.
As part of a wide strategic partnership with the UK Government, Moderna has established the Vaccine Innovation Fund, a multimillion-pound fund to invest in sustaining and enhancing the UK's capabilities in vaccine research beyond the immediate crisis of the pandemic.
Contact
Contact
Development of the UK Vaccine Innovation Pathway and management of the Vaccine Innovation Fund are being led by a dedicated UK Programme Management Office, led by Dr Maria Koufali, which will be working closely with research delivery infrastructure and other key stakeholders across the UK.
For more information about the development of the Pathway please contact us at vip@nihr.ac.uk to sign up for our newsletters, or to apply to join a forum.
Page updated
Report abuse